Premium
Pityriasis rubra pilaris‐like reaction induced by imatinib
Author(s) -
Plana A.,
Carrascosa J. M.,
Vilavella M.,
Ferrandiz C.
Publication year - 2013
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12081
Subject(s) - pityriasis rubra pilaris , imatinib , medicine , gist , dermatology , drug eruption , dermatofibrosarcoma protuberans , nilotinib , imatinib mesylate , adverse effect , drug reaction , myeloid leukemia , drug , stromal cell , immunology , pathology , pharmacology , psoriasis
Summary Imatinib, a kinase inhibitor, is currently approved for the treatment of chronic myeloid leukaemia, gastrointestinal stromal tumours ( GIST ), and other malignant conditions such as dermatofibrosarcoma protuberans. Treatment with imatinib is generally well tolerated, but some cutaneous adverse events ( AE s), such as exanthematous papular eruptions and Stevens–Johnson syndrome have been reported. We report a case of a pityriasis rubra pilaris ( PRP )‐like eruption associated with this drug. Although cutaneous AE s associated with imatinib are relatively common (up to 69% of cases), no previous cases of PRP ‐like eruptions related to this drug have been described previously, to our knowledge.